GoodRx Holdings Inc (GDRX) Stock Price, Trades & News

GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.

Financial Strength

5/10

Name	Current	Vs Industry
Cash-To-Debt	0.44
Equity-to-Asset	0.31
Debt-to-Equity	0.87
Debt-to-EBITDA	3.12
Interest Coverage	1.87
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	0.19	Distress Grey Safe
Beneish M-Score	-2.76	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

4/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	6.3
	3-Year EBITDA Growth Rate	48.4
	3-Year EPS without NRI Growth Rate	5.3
	3-Year FCF Growth Rate	5.8
	3-Year Book Growth Rate	-4.1
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	7.65
	Future 3-5Y Total Revenue Growth Rate Estimate	3.6

Momentum Rank

5/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	64.14
	9-Day RSI	57.94
	14-Day RSI	55.95
	3-1 Month Momentum %	36.27
	6-1 Month Momentum %	1.09
	12-1 Month Momentum %	-43.61

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.47
	Quick Ratio	1.47
	Cash Ratio	0.27
	Days Sales Outstanding	94.63
	Days Payable	117.14

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	4.9
	Shareholder Yield %	18.48

Profitability Rank

5/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	91.83
	Operating Margin %	9.92
	Net Margin %	2.61
	EBITDA Margin %	22
	FCF Margin %	12.25
	OCF Margin %	21.62
	ROE %	3.28
	ROA %	1.4
	ROIC %	3.2
	3-Year ROIIC %	17.95
	ROC (Joel Greenblatt) %	49.46
	ROCE %	7.46
	Years of Profitability over Past 10-Year	4
	Moat Score	6
	Tariff Resilience Score	9

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	46.67
	Forward PE Ratio	9.06
	PE Ratio without NRI	15.56
	Price-to-Owner-Earnings	103.73
	PS Ratio	1.25
	PB Ratio	1.52
	Price-to-Free-Cash-Flow	10.12
	Price-to-Operating-Cash-Flow	5.72
	EV-to-EBIT	14.37
	EV-to-Forward-EBIT	4.73
	EV-to-EBITDA	7.23
	EV-to-Forward-EBITDA	3.62
	EV-to-Revenue	1.59
	EV-to-Forward-Revenue	1.3
	EV-to-FCF	12.99
	Price-to-GF-Value	0.49
	Price-to-Projected-FCF	0.65
	Earnings Yield (Greenblatt) %	6.96
	FCF Yield %	10.18

GF Value™: $5.66

GDRX

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with GDRX. Try a 7-Day Free Trial to check it out.

GoodRx Holdings Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

GoodRx Holdings Inc Stock Events

Financials Calendars

Event	Date	Price ($)
Third quarter earnings conference call for 2026	2026-11-05 08:00	In 132 days
Third quarter earnings results for 2026	2026-11-04	In 130 days
Second quarter earnings conference call for 2026	2026-08-07 08:00	In 42 days
Second quarter earnings results for 2026	2026-08-06	In 40 days
General meeting for 2026	2026-06-16 12:00	2.73 (+0.37%)
First quarter earnings conference call for 2026	2026-05-07 08:00	2.57 (+0.00%)
First quarter earnings results for 2026	2026-05-06	2.56 (+1.99%)
Fourth quarter earnings conference call for 2025	2026-02-26 08:00	2.45 (+3.38%)
Annual report for 2025	2026-02-26	2.45 (+3.38%)
Fourth quarter earnings results for 2025	2026-02-25	2.37 (+3.95%)

Show

Entries

Guru Commentaries on NAS:GDRX

No articles.

Press Release

	Subject	Date
	GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs	2026-05-27
	GoodRx Expands Offerings to Now Include Ozempic® Pill for Type 2 Diabetes Patients	2026-05-01
	GoodRx Announces Date for First Quarter 2026 Earnings Release and Conference Call	2026-04-17
	GoodRx Now Offers Access to Wegovy® HD at $399 Per Month Self-Pay Price	2026-04-15
	GoodRx Expands Access to Eli Lilly and Company's New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide	2026-04-09
	GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications	2026-03-11
	GoodRx to Expand Employer-Sponsored Access to Zepbound® KwikPen®	2026-03-06
	GoodRx Reports Fourth Quarter and Full Year 2025 Results	2026-02-25
	GoodRx Expands Into Employer Market With Launch of “GoodRx Employer Direct”	2026-02-24
	GoodRx Powers Pricing for Leading Brand Medications on TrumpRx	2026-02-05

10/Page

Articles on GoodRx Holdings Inc

No articles.

Headlines

No news.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.